| Literature DB >> 27999264 |
Meimei Chen1,2, Fafu Yang3, Xuemei Yang4, Xinmei Lai5, Yuxing Gao6.
Abstract
Metabolic syndrome (MS) is becoming a worldwide health problem. Wendan decoction (WDD)-a famous traditional Chinese medicine formula-has been extensively employed to relieve syndromes related to MS in clinical practice in China. However, its pharmacological mechanisms still remain vague. In this study, a comprehensive approach that integrated chemomics, principal component analysis, molecular docking simulation, and network analysis was established to elucidate the multi-component and multi-target mechanism of action of WDD in treatment of MS. The compounds in WDD were found to possess chemical diversity, complexity and drug-likeness compared to MS drugs. Six nuclear receptors were obtained to have strong binding affinity with 217 compounds of five herbs in WDD. The importance roles of targets and herbs were also identified due to network parameters. Five compounds from Radix Glycyrrhizae Preparata can hit all six targets, which can assist in screening new MS drugs. The pathway network analysis demonstrated that the main pharmacological effects of WDD might lie in maintaining lipid and glucose metabolisms and anticancer activities as well as immunomodulatory and hepatoprotective effects. This study provided a comprehensive system approach for understanding the multi-component, multi-target and multi-pathway mechanisms of WDD during the treatment of MS.Entities:
Keywords: Wendan decoction; metabolic syndrome; molecular docking; network analysis
Mesh:
Substances:
Year: 2016 PMID: 27999264 PMCID: PMC5187914 DOI: 10.3390/ijms17122114
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Structural categories of ingredients in Wendan decoction (WDD).
| Subclasses | Number of Ingredients | Categories |
|---|---|---|
| Lignin | 1 | Phenylpropanoids |
| Coumarin | 47 | Phenylpropanoids |
| Flavan-3-ol | 1 | Flavonoids |
| Isoflavanone | 10 | Flavonoids |
| Anthocyanidin | 8 | Flavonoids |
| Chalcone | 16 | Flavonoids |
| Flavonol | 19 | Flavonoids |
| Isoflavone | 44 | Flavonoids |
| Flavone | 63 | Flavonoids |
| Flavanone | 53 | Flavonoids |
| Dihydrochalcone | 69 | Flavonoids |
| Imidazole | 1 | Alkaloids |
| Piperidines | 4 | Alkaloids |
| Quinolines | 4 | Alkaloids |
| Indoles | 5 | Alkaloids |
| Pyrrolidines | 12 | Alkaloids |
| Six carbon aldose | 99 | Sugars |
| Five carbon aldose | 103 | Sugars |
| Annular monoterpene | 90 | Terpenoids |
| Open chain monoterpene | 10 | Terpenoids |
| Diterpene | 96 | Terpenoids |
Drug-like property descriptors of compounds in WDD.
| Descriptors | Meaning | Median | Mean | Std. Deviation |
|---|---|---|---|---|
| Weight | Molecular weight | 388.47 | 413.40 | 179.80 |
| a_acc | Number of hydrogen bond acceptor atoms | 5 | 5.59 | 4.08 |
| a_don | Number of hydrogen bond donor atoms | 2 | 3.17 | 2.83 |
| b_rotN | Number of rotatable bonds | 5 | 5.26 | 3.80 |
| logP( | Log of the octanol/water partition coefficient | 3.28 | 3.24 | 2.83 |
Figure 1Comparing chemical characteristics of ingredients in WDD versus metabolic syndrome (MS) drugs. (A–E) are distributions of drug-like properties of ingredients in WDD and MS drugs; (F) chemical space distribution of WDD versus MS drugs by principal component analysis (PCA).
Docking results of WDD.
| Herbs | Hit Targets | Number of Bioactive Compounds |
|---|---|---|
| PPARα, PPARβ, PPARγ, LXRα, LXRβ, RXRα | 118 | |
| PPARα, PPARβ, PPARγ, LXRα, LXRβ | 42 | |
| PPARα, PPARβ, PPARγ, LXRα, LXRβ | 35 | |
| PPARα, PPARβ, PPARγ, LXRα, LXRβ | 18 | |
| PPARα, PPARβ, PPARγ, LXRα, LXRβ | 3 |
Figure 2The herb-compound-target network: the pink round nodes refer to compounds from herbs; the yellow rhombic nodes represent herbs; the green quadrate nodes represent targets.
Network features of targets and herbs in the herb-compound-target network.
| Code | Node | Degree | Betweenness |
|---|---|---|---|
| 2P54 | PPARα | 67 | 0.0537 |
| 2I4J | PPARγ | 145 | 0.3741 |
| 3UVV | RXRα | 9 | 0.0007 |
| 3IKM | PPARΔ | 48 | 0.0235 |
| 3IPU | LXRα | 128 | 0.3283 |
| 1PQC | LXRβ | 62 | 0.0921 |
| RGP | 118 | 0.2311 | |
| PC | 42 | 0.0264 | |
| CA | 35 | 0.0232 | |
| PCR | 18 | 0.0074 | |
| PT | 3 | 0.0001 |
Figure 3Degree distribution between compounds and targets.
Five compounds with the highest degree distribution between compounds and targets.
| Chemical Name | Herb Source | Degree | Bioactivity |
|---|---|---|---|
| Glabrol | Radix Glycyrrhizae Preparata | 6 | Activation of PPARγ and Drd3, and inhibition of TPNT1 and PTP1B. |
| Euchrestaflavanone A | Radix Glycyrrhizae Preparata | 6 | Inhibition of TPNT1 and PTP1B, and cytotoxic activity, antimicrobial activity |
| Euchrenone a5 | Radix Glycyrrhizae Preparata | 6 | Activation of PPARγ |
| Glyinflanin D | Radix Glycyrrhizae Preparata | 6 | Unreported |
| 1-(7-Hydroxy-2,2-dimethyl-2 | Radix Glycyrrhizae Preparata | 6 | Cytotoxic activity |
Figure 4The herb-target-pathway network: the pink round nodes referred to pathways; the yellow rhombic nodes represent herbs; the green quadrate nodes represent targets.
19 Kyoto Encyclopedia of Genes and Genomes KEGG pathways associated with 6 predicted targets of WDD.
| Pathway ID | Term | Pathway Class | Degree |
|---|---|---|---|
| hsa03320 | PPAR signaling pathway | Endocrine system | 6 |
| hsa04919 | Thyroid hormone signaling pathway | Endocrine system | 1 |
| hsa04920 | Adipocytokine signaling pathway | Endocrine system | 2 |
| hsa0492 | Glucagon signaling pathway | Endocrine system | 1 |
| hsa04932 | Non-alcoholic fatty liver disease (NAFLD) | Endocrine and metabolic diseases | 4 |
| hsa04024 | cAMP signaling pathway | Signal transduction | 1 |
| hsa04151 | PI3K-Akt signaling pathway | Signal transduction | 1 |
| hsa04152 | AMPK signaling pathway | Signal transduction | 1 |
| hsa04310 | Wnt signaling pathway | Signal transduction | 1 |
| hsa04380 | Osteoclast differentiation | Development | 1 |
| hsa04976 | Bile secretion | Digestive system | 1 |
| hsa05016 | Huntington’s disease | Neurodegenerative diseases | 1 |
| hsa05160 | Hepatitis C | Infectious diseases | 4 |
| hsa05200 | Pathways in cancer | Cancers | 3 |
| hsa05202 | Transcriptional misregulation in cancer | Cancers | 2 |
| hsa05216 | Thyroid cancer | Cancers | 2 |
| hsa05221 | Acute myeloid leukemia | Cancers | 1 |
| hsa05222 | Small cell lung cancer | Cancers | 1 |
| hsa05223 | Non-small cell lung cancer | Cancers | 1 |